Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD



Rating:

Share or cite this content

Citations should be made in the following way:
E. Bateman (Cape Town, South Africa), I. Pavord (Oxford, United Kingdom), W. Busse (Madison, United States of America), N. Daizadeh (Cambridge, United States of America), Y. Deniz (Tarrytown, United States of America), P. Rowe (Bridgewater, United States of America), J. Jacob-Nara (Cambridge/Bridgewater, United States of America), R. Gall (Tarrytown, United States of America), N. Pandit-Abid (Bridgewater, United States of America), B. Ortiz (Tarrytown, United States of America). Dupilumab efficacy in patients with GINA-defined type 2 asthma: TRAVERSE. 2837

Member's Comments

No comment yet.

Related content which might interest you: ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Noneosinophilic asthma: persistence over time and effect of treatment Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006 Cough variant asthma: prevalence and outcome of specific therapy Source: Eur Respir J 2004; 24: Suppl. 48, 589s Year: 2004 Prevalence of atopy and respiratory symptoms in type 1 diabetes mellitus (T1DM) patients Source: Annual Congress 2005 - Environmental factors, allergy and asthma Year: 2005 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 The prevalence of subtypes of type-2 inflammation in a real-life population of patients with difficult-to-control asthma Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 A comparison of clinical characteristics between cough variant asthma (CVA) and bronchial asthma (BA) in adult patients Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010 Study of the connection between COPD, bronchial asthma and diabetes mellitus types 1 and 2 Source: Annual Congress 2009 - Asthma and comorbid conditions Year: 2009 Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma Source: Eur Respir J, 58 (4) 2004605; 10.1183/13993003.04605-2020 Year: 2021 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004